Beijing Luzhu Biotechnology Company Limited is engaged in drug discovery, research and development and commercialization. The company’s main products and services include out-licensing human vaccines and therapeutic biologics, and its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The company was established in 2001 and is headquartered in Beijing City, China.
Headquarters
5/F, Manulife Place, 348 Kwun Tong Road
Hong Kong; Hong Kong;
Contact Details: Purchase the Beijing Luzhu Biotechnology Company Limited report to view the information.
Website: http://www.luzhubiotech.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service